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Abstract
The RACCAM FFAG project is described, its context,
partners, on-going activities, plans, etc.
THE RACCAM PROJECT
The RACCAM (Recherche en ACCe´le´rateurs et
Applications Me´dicales) project has recently been funded,
for a three years term (2006-2008), by the French National
Research Agency (ANR). RACCAM is a tripartite collab-
oration, involving:
(i) the CNRS Laboratory IN2P3/LPSC [1]
(ii) the French magnet industrial SIGMAPHI [2] and
(iii) the Radiation Oncology Department of Grenoble Uni-
versity Hospital [3].
The project concerns fixed field alternating gradient
(FFAG) accelerator R&D on the one hand, from lattice de-
sign to magnet prototyping, and on the other hand their
application as hadrontherapy for cancer and for radio-
biological researches.
RACCAM’s goal is three-fold:
(i) participate to the on-going international collaborations
in the field of FFAGs and recent concepts of ”non-scaling”
FFAGs, with frames for instance, the Neutrino Factory
(NuFact), the EMMA project of an electron model of a
muon FFAG accelerator, etc.
(ii) design, build and experiment a prototype of an FFAG
magnet proper to fulfil the requirements of rapid cycling
acceleration with relevant momentum bite and geometrical
acceptance
(iii) develop the concepts, and show the feasibility, of the
application of such FFAG beams to anti-cancer hadronther-
apy and to researches in radiobiology.
The RACCAM project has its web site,
http://wwwlpsc.in2p3.fr/RACCAM/, where various
information, schedules, meetings, on-going activities, etc.
are regularly up-dated.
CONTEXT
FFAGs are based on the use of magnets with field con-
stant in time, by contrast with pulsed synchrotrons (e.g. re-
cent hadrontherapy installations, LHC) of which magnetic
field increases in synchronism with particle acceleration.
The unique properties of FFAGs have caused a regain of
interest in the last years [4], motivated in particular by re-
cent progress in high gradient accelerating systems, in 3D
magnet computation codes [5], and by modern concepts as
”non-scaling” optics and fast acceleration [6].
FFAGs are fast cycling accelerators (kHz range), with
enormous geometrical and momentum acceptance. The
combination of these two properties yields high average in-
tensity beams ; in addition the quality of the manipulation
of beams is that of synchrotrons : strong focusing, variable
energy, efficiency of transmission and extraction.
This context, as well as on-going works in the frame of
the international collaboration on the rapid acceleration of
muons in the neutrino factory [7, 8], has seen the birth of
a project of a 10-20 MeV electron demonstrator [9]. This
electron model could be based in UK [9], and would aim at
proving the feasibility of the innovative concepts of ”non-
scaling” optics and fast acceleration.
FFAGs are in various types of applications a credible
concurrent of cyclotron, Linac and pulsed synchrotron ac-
celerators, as an answer to the present needs in high average
intensity beams, and offers variable energy as desirable in
medical applications.
The goal of the RACCAM project is to contribute to the
FFAG R&D within the on-going international collabora-
tions, in Europe by contributing to the electron model of a
non-scaling FFAG, in domains as beam dynamics studies,
machine design, and by the realisation of a prototype of an
FFAG magnet. In addition, RACCAM has the ambition of
studying the application of FFAGs in the medical domain,
as a second generation proton and light ion accelerator for
cancer treatment by radiotherapy.
If a technological breakthrough could make proton
beams easily available to radiotherapy, protons would to-
tally dominate radiotherapy and would undoubtedly repre-
sent in the future more than two thirds of the indications,
if not even more. This is a domain with potentially very
strong development, with purely technical and economical
constraints.
The interest of these accelerators is in there potential-
ity to being simpler to build and to operate, more compact,
more performing, cheaper than conventional synchrotrons,
with proton dose rates comparable to cyclotron ones, and
with variable energy allowing 3D conformational irradia-
tion of tumors (“active scanning”).
RECENT ACTIVITIES, PLANS FOR
FUTURE
In matter of lattice design the RACCAM team is collab-
orating within the Neutrino Factory, the ISS-NuFact [7, 8]
and the EMMA [9] networks.
The main activities for the moment are related to com-
puter code developments, and in general application to
transmission simulations and other design optimizations.
They have concerned up to now most types of lattices en-
countered in these domains : linear non-scaling [10, 11],
scaling [12], isochronous pumplet and electron model [12,
13].
An important orientation of the project has been decided,
from the very beginning : dedicate substantial work to spi-
ral scaling type FFAG lattice, as it is liable to yield very
compact machines, consistent with the medical applica-
tions foreseen within RACCAM. It is worth noting that
this type of lattice belongs in many projects as the accel-
eration of muons in the Japanese version of the neutrino
factory [14], proton drivers [15], proton beams for hadron-
therapy. As a consequence, design activities, computing
tools developments, are being started.
In matter of magnet design and prototyping, a conse-
quence of the interest of spiral type of scaling lattice, is that
RACCAM now foresees magnet prototyping in this area.
Various directions of studies have been launched, from for-
mal modelling [16] to 2-D and 3-D computations, which
should lead in the coming months to a viable design of a
spiral magnet in the 100 MeV region of optics.
On the other hand, works are undertaken to explore the
FFAG applications for anti-cancer treatments. The origi-
nality of FFAG as compact machines with high dose rate
proton beam of various energies offers a new point of view
to look at tomorrow’s radiotherapy. Biological conditions
for high dose rate treatments will be studied, including cell
radio-sensitivity alterations according to the dose rate, the
dose per fraction and the tumor biology. The public health
impact and the economical conditions of the deployment
of this next generation of machines will be studied. Fi-
nally, specifications of the prototype will take into account
the requirements for medical and biological experimental
applications. As a first approach, a 10 X 10 cm beam with
at least 70 MeV/u of energy (permitting a depth of 35 to 40
mm in human tissues), able to deliver 1 to 10 Gy / sec/litre
or 1 to 2 Gy / bunch of protons will be tentative character-
istics of the prototype.
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